A Chinese court on Friday fined British drugmaker GlaxoSmithKline 3.0 billion yuan ($490 million) following a nearly year-long bribery probe, state media said.
The fine, levied by the Changsha Intermediate People's Court after a closed hearing in central China's Hunan province, was the largest such penalty ever, China's official Xinhua news agency reported.
Chinese authorities had accused GSK employees of bribing hospitals, doctors and health institutions to gain billions of dollars in illegal revenue.